WEE1 and endometrial serous adenocarcinoma: Studies of Wee1 inhibition in uterine serous carcinoma, which shares many of the same molecular alterations as UCS, have reported evidence of clinical activity with phase II studies show objective response rates (ORR) of 25–29 % (Liu et al., 2021, Funda Meric-Bernstam et al., 2022, Liu et al., 2023).